Please ensure Javascript is enabled for purposes of website accessibility

제품별 브라우징

추천 콘텐츠

박테리아 및 바이러스 관련 제품
abinScience는 모노키복스, 에볼라 및 기타 신흥 병원체를 포함한 바이러스, 슈퍼박테리아 및 기생충 연구를 위한 고품질 도구를 제공하며, 진단, 백신 개발 및 치료법 발견을 지원합니다.
신경과학
abinScience는 알츠하이머병, 파킨슨병 및 헌팅턴병 연구를 위한 도구를 제공하며, 신경과학 분야의 바이오마커, 진단 및 치료법 개발을 지원합니다.
치료 표적
abinScience는 CD3E, CTLA4, PD1, PDL1, B7-H3, CEA, CD200R1, SIRPA 및 CCR8을 포함한 치료 표적 연구용 도구를 제공하며, 바이오마커, 진단 및 치료법 개발을 지원합니다.
DNA/RNA 연구용 항체
abinScience는 항dsRNA 항체(J2, K1, K2)를 제공하며, 이는 바이러스학, 면역학 및 RNA 연구 분야에서 뛰어난 특이성과 감도로 널리 인식되어 과학자들이 RNA 세계를 탐구하는 데 힘을 줍니다.
생물독소 항체
보툴리눔, 리신, 파상풍 및 기타 독소에 대한 신뢰할 수 있는 항체를 제공하며, 감도 높은 검출 및 독소 연구를支援합니다.
자가면역 질환
TNF-α, IL-6, IFN-γ, PD-1 및 CTLA-4와 같은 주요 표적에 대한 고특이성 항체 및 ELISA 키트를 제공하며, 신뢰할 수 있는 사이토카인 검출 및 면역 조절 연구를支援합니다.
MHC 복합체
MHC 클래스 I 및 클래스 II 시약 — 면역학 및 이식 연구를 위한 HLA 단백질 및 항체. abinScience.
TACAs 항체
종양 관련 탄수화물 항원을 표적으로 하는 항체 — 암 면역학 및 당생물학 연구용. abinScience.
모델 생물
모델 생물(제브라피쉬, 개, 돼지, 조류, 아프리카발톱개구리, 식물 종)을 위한 종 특이적 항체 및 단백질. abinScience.

abinScience에 관하여

뉴스

  • IL-6 Signaling Pathway Explained: A Research Reagent Guide from Ligand to Transcription
    The IL-6/IL-6R/gp130 axis is one of the most clinically validated cytokine pathways in inflammation research, targeted by a growing roster of approved and investigational biologics. This guide maps the pathway node by node — ligand, α-receptor, gp130 signal transducer, and downstream JAK/STAT3 signaling — and matches each step to available reagents, highlighting an InVivoMAb-grade in vivo neutralizing antibody and a reference antibody panel spanning Ziltivekimab, Sirukumab, Olokizumab, and Levilimab for biosimilar benchmarking.
  • After the Floodwaters Recede: The Hidden Infectious Disease Risks Lurking in Standing Water
    Floodwaters bring more than immediate destruction — the period after they recede is often a high-risk window for infectious disease outbreaks, driven by prolonged water contact, sewage contamination, mosquito proliferation, and damaged sanitation infrastructure. This article takes a research-oriented look at five infectious diseases commonly associated with post-flood conditions: cholera, leptospirosis, malaria, Chikungunya fever, and Clostridioides difficile infection. It examines the core pathogenic mechanisms behind each disease — including cholera toxin–receptor binding, PfEMP1-mediated red blood cell adhesion in malaria, CHIKV E2 protein-driven cell entry, and TcdB toxin recognition of Frizzled receptors — while summarizing recent advances in antibody, vaccine, and therapeutic development, offering researchers a concise reference for post-disaster infectious disease research.
  • CHIKV Research Tools After the Ixchiq Vaccine Suspension: Antibodies, Proteins & ELISA Kits
    With the FDA's suspension of the first approved chikungunya vaccine following serious safety concerns, reliable serological and diagnostic tools have taken on renewed importance for CHIKV surveillance and research. This guide covers abinScience's newly added Human IgG ELISA Kit alongside existing E1/E2 glycoprotein antibodies and proteins, an InVivoMAb-grade neutralizing antibody, and non-structural protein reagents for teams studying viral replication and antiviral mechanisms.
  • Bispecific Antibodies for Research: From PD-L1×CD3 T Cell Engagers to Dual-Checkpoint Blockade
    T cell engaging bispecific antibodies have moved from a niche engineering concept to a leading drug development strategy, and PD-L1×CD3 formats are extending this approach beyond hematologic targets into solid tumors. This guide introduces abinScience's newly added PD-L1×CD3 bispecific antibodies and surveys the broader 161-product bispecific catalog, including CD19/CD20×CD3 reference antibodies for approved T cell engagers and dual-checkpoint bispecifics (CTLA-4×PD-1, PD-1×VEGF) for combination blockade research.
  • Canine PD-L1 Antibody: A New Comparative Oncology Tool for Veterinary Cancer Research
    With the USDA's conditional licensure of the first anti-PD-1 antibody for canine mast cell tumors and melanoma, checkpoint blockade has moved from research concept to clinical reality in veterinary oncology. This guide introduces abinScience's newly added Anti-Canine PD-L1 antibody (clone 12C10E4) and surveys the broader 220-product canine checkpoint toolkit — including PD-1, CTLA-4, LAG-3, TIM-3, and HER2 reagents — supporting both spontaneous canine tumor models and comparative immuno-oncology research relevant to human therapeutic development.
  • Anti-IL-17A Antibody Selection Guide: Clone Comparison for WB, ELISA, IHC & In Vivo
    Not every anti-IL-17A antibody works for every application—a polyclonal built for Western blot won't perform in vivo, and an InVivoMAb-grade clone isn't optimized for IHC. This guide breaks down IL-17A antibody selection by application, comparing polyclonal antibodies for WB/IHC/ELISA; directly conjugated monoclonals for flow cytometry; InVivoMAb vs. InVivo Plus grades for neutralization studies; and reference antibodies for biosimilar benchmarking—including the newly added Bimekizumab reference antibody and mouse IL-17A recombinant protein.
  • How to Set Up a Sandwich ELISA for C. difficile Toxin A Detection: A Step-by-Step Protocol
    Detecting Clostridioides difficile Toxin A/tcdA reliably starts with a validated antibody pair and a properly reconstituted reference standard. This step-by-step guide walks through setting up a sandwich ELISA from plate coating through TMB development and 4-PL curve fitting, using a matched capture/detection antibody pair and a recombinant tcdA reference protein — with troubleshooting tips for background, weak standard curves, and complex sample matrices like stool eluates.
  • Functional Assay Validation Guide: Choosing the Right Recombinant Protein for Bioactivity Testing
    Not all recombinant proteins that pass a purity check will perform in a functional assay — the expression system used to manufacture them determines whether critical folding and glycosylation requirements are met. This guide breaks down when mammalian cell expression is essential versus when E. coli-derived protein retains full bioactivity, walks through a practical validation workflow using dose-response curves and orthogonal binding methods, and highlights abinScience's GMP-grade recombinant proteins with published ED50 data across both expression systems.
  • Reference Antibodies for Biosimilar Development: How to Select and Use RUO Standards in Your Characterization Workflow
    Reference Antibody, Research Use Only, Biosimilar Characterization, Anti-Drug Antibody Assay, Analytical Similarity, Functional Bioassay, oxMIF, GPC3, FOLR1, IL-6, TMPRSS6, Recombinant Monoclonal Antibody
  • Semaglutide vs Tirzepatide vs Retatrutide: ELISA Kits for GLP-1 Drug Research
    This guide compares semaglutide, tirzepatide, and retatrutide from a research reagent perspective — covering PK ELISA kits, ADA immunogenicity assays, receptor antibodies, and biosimilar reference standards for preclinical and translational studies.
  • p16INK4a (CDKN2A) Antibodies & Nanobodies — Senescence & Tumor Suppressor Research
    Anti-p16INK4a/CDKN2A antibodies, VHH nanobodies, and recombinant proteins from abinScience. Polyclonal antibodies for human and mouse, nanobody SAA2259 for enhanced IHC tissue penetration, plus His-tagged and GST-tagged p16 proteins for assay controls and CDK inhibition studies.
  • From GLP-1 to the Multi-Target Era: ADA 2026 Unveils New Directions in Weight-Loss Drug R&D
    ADA 2026 highlights the shift from single-target GLP-1RAs to multi-target agonists (dual/triple), oral small molecules, and ultra-long-acting injectables. The latest triple-agonist data (LY3437943) show >30% weight loss, while biased oral agonists improve tolerability. Multi-target synergy, oral convenience, and neuroimaging deepen efficacy and mechanistic understanding.